May. 2 at 10:20 PM
$ALZN
On March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “Company”) received a letter (the “Letter”) from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least
$2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of January 31, 2026 was approximately
$2.2 million.
In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 4, 2026, to submit a plan to regain compliance
